Gene · 4070
Papers3,230
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
501 to 520 of 3,230
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Emerging trends in synthesis, characterization, and mechanism of action of antibody-drug and antibody-nanoparticle conjugates. | Discov Nano | 2025 | 40824329 | PubTator, text mining | PubMed |
| Expression and Prognostic Significance of Different Antibody-Drug Conjugate Target Proteins in Urachal Carcinoma. | Clin Genitourin Cancer | 2025 | 40819477 | PubTator, text mining | PubMed |
| The role of m5C, m1A and m7G modifications in tumors of urinary system. | Front Cell Dev Biol | 2025 | 40809690 | PubTator, text mining | PubMed |
| Case Report: Personalized treatment in stage IV breast cancer using the patient-derived organoids. | Front Oncol | 2025 | 40809034 | PubTator, text mining | PubMed |
| Multiplex Immunofluorescence Reveals Therapeutic Targets EGFR, EpCAM, Tissue Factor, and TROP2 in Triple-Negative Breast Cancer. | Int J Mol Sci | 2025 | 40806559 | PubTator, text mining | PubMed |
| Tumour extracellular vesicle surface Protein-mRNA integration assay for early detection of epithelial ovarian cancer. | EBioMedicine | 2025 | 40803203 | PubTator, text mining | PubMed |
| Datopotamab deruxtecan induces hallmarks of immunogenic cell death. | Cell Stress | 2025 | 40800161 | PubTator, text mining | PubMed |
| A tale of two TROP-2 antibody-drug conjugates: a comparative saga of datopotamab deruxtecan and sacituzumab govitecan. | Oncologist | 2025 | 40795027 | PubTator, text mining | PubMed |
| Energy Decomposition-Driven Design of Trop2-Targeting Peptide. | Cell Biochem Biophys | 2025 | 40779128 | PubTator, text mining | PubMed |
| Cost-effectiveness of sacituzumab tirumotecan versus chemotherapy for patients with metastatic triple-negative breast cancer in China. | Breast | 2025 | 40768820 | PubTator, text mining | PubMed |
| SLFN11: a pan-cancer biomarker for DNA-targeted drugs sensitivity and therapeutic strategy guidance. | Front Oncol | 2025 | 40766331 | PubTator, text mining | PubMed |
| Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non-Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy. | Cancer Discov | 2025 | 40762432 | PubTator, text mining | PubMed |
| Preclinical Pharmacokinetic, Pharmacodynamic, and Safety Profile of OBI-992: A Novel TROP2-Targeted Antibody-Drug Conjugate. | Mol Cancer Ther | 2025 | 40762235 | PubTator, text mining | PubMed |
| Established and emerging biomarkers approaches in urothelial carcinoma. | Expert Rev Anticancer Ther | 2025 | 40762048 | PubTator, text mining | PubMed |
| Proteogenomic characterization unveils biomarkers associated with chemoresistance in muscle-invasive bladder cancer. | Cell Rep Med | 2025 | 40749681 | PubTator, text mining | PubMed |
| New Insights into Potential Therapeutic Targets for Neuroendocrine Prostate Cancer: From Bench to Clinic. | Research (Wash D C) | 2025 | 40746825 | PubTator, text mining | PubMed |
| Was kommt nach CDK4/6-Inhibition? Perspektiven beim fortgeschrittenen Mammakarzinom. | Wien Klin Wochenschr | 2025 | 40742511 | PubTator, text mining | PubMed |
| High Trop-2 expression in pulmonary sarcomatoid carcinoma reveals antibody-drug conjugate targeting Trop-2 is a promising therapeutic approach. | J Transl Med | 2025 | 40739577 | PubTator, text mining | PubMed |
| Antibody-drug conjugates for treating early-stage breast cancer: current use, anticipated evolutions. | NPJ Breast Cancer | 2025 | 40739147 | PubTator, text mining | PubMed |
| Serological diagnosis of cysticercosis in humans and pigs: status, limitations, and prospects. | Front Vet Sci | 2025 | 40735286 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4070/papers?page=26